A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)

RCT (n=1,091) reports non-inferiority for change from baseline in HbA1c at 16 weeks for faster aspart (Fiasp) vs. insulin aspart (both in combination with insulin degludec); estimated treatment difference −0.04% [95% CI −0.11 to 0.03]; p< 0.001.


Diabetes Care